Ista reports Phase II/III allergic conjunctivitis data

ISTA said bepotastine met one of two primary endpoints in a U.S. Phase II/III trial to treat allergic conjunctivitis. In the double-blind, placebo-controlled study, both 1.0% and 1.5% concentrations o...